A Randomized Open-label Phase II Multicenter Trial Assessing the Efficacy and Safety of tamOxifen Plus LY2228820 in Advanced or Metastatic Breast Cancer Progressing on aromatasE Inhibitors
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 8
- 试验地点
- 14
- 主要终点
- To define the efficacy (progression-free survival rate at 6 months) of LY2228820 in combination with tamoxifen for postmenopausal women with an ER positive and HER2 negative advanced or metastatic breast cancer who progressed on aromatase inhibitors.
研究概览
简要总结
Metastatic breast cancer (MBC) remains an incurable disease and despite an improvement of the effect of systemic treatments. After relapse on first-line non-steroidal aromatase inhibitor, current clinical practice and treatment guidelines include tamoxifen, fulvestrant (an ER antagonist) and exemestane as available options (NCCN treatment guidelines 2012), but in this context of resistance, their efficacy are poor.
Some results confirm the possibility to improve the efficacy of tamoxifen in metastatic setting by a combination with therapy targeting signal transduction pathways. Other transduction pathways seem to be involved in endocrine sensitivity/resistance, such as RAS/RAF/MEK/MAK pathway.
LY2228820 inhibits the activity of p38 MAPK (selective inhibitor of the α and β isoforms of p38 MAPK in vitro) and reduces phosphorylation of its cellular target, MAPK-activated protein kinase 2 (MAPKAP-K2).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Women with histologically confirmed breast cancer
- •18 < age < 80 years old
- •Menopausal status Women are considered post-menopausal and not of child bearing potential if they have had
- •12 months of spontaneous amenorrhea with an appropriate clinical profile (e.g., age appropriate, history of vasomotor symptoms) or
- •6 months of spontaneous amenorrhea with serum FSH levels > 40 mIU/mL and estradiol < 20 pg/mL or
- •surgical bilateral oophorectomy (with or without hysterectomy) at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential
- •ER-positive status by local laboratory testing (>10% by IHC) and HER2-negative status (IHC 0 or 1+ or 2+ and FISH negative) on the last biopsy or surgical specimen available.
- •Disease progression defined as inoperable locally advanced or metastatic breast cancer (MBC) excluding aggressive visceral disease requiring other approaches, such as chemotherapy
- •Disease refractory to aromatase inhibitors (AI) defined as:
- •recurrence while on, or within 12 months of end of adjuvant treatment with aromatase inhibitor, or
- •progression while on, or within 3 months of end of AI for locally advanced or MBC
- •Patients who have received fulvestrant are eligible
- •Maximum 2 previous lines of chemotherapy for MBC
- •Performance Status (PS) ≤ 2
- •Patient able to swallow and retain oral medication
- •Measurable or evaluable lesions as per RECIST 1.1
- •Measurable disease (≥ 20 mm by conventional techniques or ≥ 10 mm by spiral computed tomography scan) or
- •Non-measurable lytic or mixed (lytic + blastic) bone lesions in the absence of measurable disease.
- •Patients with only pleural effusion and/or ascites are not eligible.
- •Adequate bone marrow and organ function as defined by the following laboratory values:
- •Absolute Neutrophil Count (ANC) ≥ 1.0 x 109/L
- •Platelets (plt) ≥ 100 x 109/L
- •Hemoglobin (Hgb) ≥ 9 g/dl
- •INR ≤ 1.5 without any anticoagulation treatment
- •Serum creatinine ≤ 1.5 x ULN
- •Alanine aminotransferase (AST) and aspartate aminotransferase (ALT) within normal range (or < 3.0 x ULN if liver metastases are present)
- •Total serum bilirubin within normal range (or ≤ 1.5 x ULN if liver metastases are present; or total bilirubin ≤ 3.0 x ULN with direct bilirubin within normal range in patients with well documented Gilbert's Syndrome, which is defined as presence of several episodes of unconjugated hyperbilirubinemia with normal results from CBC count (including normal reticulocyte count and blood smear), normal liver function test results, and absence of other contributing disease processes at the time of diagnosis
- •Patient has signed informed consents obtained before any trial related activities and according to local guidelines
排除标准
- •• Previous treatment with p38 MAPK inhibitors or Tamoxifen in metastatic setting (adjuvant treatment by tamoxifen is allowed)
- •More than 2 lines of chemotherapy for locally advanced and/or metastatic breast cancer
- •Brain metastasis
- •Other malignancy (with the exception of adequately treated, basal or squamous cell carcinoma, non-melanomatous skin cancer or curatively resected cervical cancer).
- •Clinically significant (i.e. active) cardiovascular disease: cerebro-vascular accident/stroke or myocardial infarction within 6 months prior to first study medication; unstable angina; CHF of New York Heart Association (NYHA) Grade II or higher; or serious cardiac arrhythmia requiring medication.
- •Have had a major bowel resection that would alter oral drug absorption.
- •Have a diagnosis of inflammatory bowel disease (Crohn's disease or ulcerative colitis).
- •Are receiving concurrent administration of immunosuppressive therapy
- •Concurrent participation in any therapeutic clinical trial
- •Assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol
研究组 & 干预措施
TAMOXIFEN
Tamoxifen will be administered daily orally
Patients will receive study medication until disease progression or unacceptable toxicity
干预措施: Tamoxifen (Drug)
TAMOXIFEN + LY2228820
Tamoxifen will be administered daily orally LY2228820 dimesylate (Ralimetinib) will be administered orally
Patients will receive study medication until disease progression or unacceptable toxicity
干预措施: Tamoxifen (Drug)
TAMOXIFEN + LY2228820
Tamoxifen will be administered daily orally LY2228820 dimesylate (Ralimetinib) will be administered orally
Patients will receive study medication until disease progression or unacceptable toxicity
干预措施: Ralimetinib (LY2228820 dimesylate) (Drug)
结局指标
主要结局
To define the efficacy (progression-free survival rate at 6 months) of LY2228820 in combination with tamoxifen for postmenopausal women with an ER positive and HER2 negative advanced or metastatic breast cancer who progressed on aromatase inhibitors.
时间窗: at 6 months after treatment start.
次要结局
- - To evaluate the toxicity profile (Safety and Tolerability) of the LY2228820 in combination with tamoxifen(From date of randomization until study participation (during average 12 months))
- - To estimate the Progression-Free Survival of the LY2228820 in combination with tamoxifen(evaluated every 8-12 weeks (during average 12 months))
- - To assess response duration of the LY2228820 in combination with tamoxifen(evaluated every 8-12 weeks during treatment to progression or death for any cause.(during average 12 months))
- - To assess the overall survival of the LY2228820 in combination with tamoxifen(From date of randomization until the date of first documented date of death from any cause, whichever came first, assessed up to 60 months)